Avadel Pharmaceuticals to present new data on LUMRYZ

Avadel Pharmaceuticals (AVDL) announced that new data supporting the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16 posters at World Sleep 2025, taking place September 5-10, in Singapore. Additional highlights from the presentations at World Sleep 2025 include: Updated and new results from an interim descriptive analysis of data from REFRESH, a prospective multicenter, real-world study in patients with narcolepsy; Results showed that participants experienced clinically meaningful improvements in Epworth Sleepiness Scale scores, a measure of excessive daytime sleepiness, to within the normal range; REFRESH study participants experienced a reduction in severity from moderate at the start of the study to mild at study end for the pentad of narcolepsy symptoms measured on the Narcolepsy Severity Scale and reduced interference across domains on the Sheehan Disability Scale; After completing 4 months of therapy, 70% and 76% of switch participants and 90% and 87% of non-switch participants were improved on the Patient Global Impression of Change and the Clinician Global Impression of Change, respectively; Additional interim results from a study questionnaire and end of study survey showed that overall quality of life, fatigue, brain fog, depression, anxiety, and mood improved and as-needed use of stimulants was reduced; To characterize the comorbidities of patients with narcolepsy, an analysis of aggregate patient data from electronic health records was conducted at Duke University.